Neurocrine Biosciences Presents New Post-Hoc Analysis: Treatment with INGREZZA® (valbenazine) Capsules Achieves Earlier Remission of Tardive Dyskinesia Symptoms While Reducing Patient-Reported Disease Burden

SAN DIEGO, Sept. 23, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data from a post-hoc analysis of the Phase 4 KINECT-PRO™ open-label study confirming that robust rates of symptomatic remission of tardive dyskinesia were achieved with once-daily INGREZZA^® (valbenazine) capsules. The analysis also showed sustained improvements in patient-reported outcomes among participants who achieved symptomatic remission. These results were presented at Psych Congress 2025 in San Diego.

Read more at prnewswire.com